Form 8-K ALIMERA SCIENCES INC For: Aug 10
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 10, 2015
ALIMERA SCIENCES, INC.
(Exact name of registrant as specified in its charter)
(Exact name of registrant as specified in its charter)
Delaware | 001-34703 | 20-0028718 | ||||
(State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||
6120 Windward Parkway Suite 290 Alpharetta, Georgia | 30005 | |||||
(Address of Principal Executive Offices) | (Zip Code) | |||||
Registrant’s telephone number, including area code: (678) 990-5740
Not Applicable |
(Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 10, 2015, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the second quarter ended June 30, 2015. Alimera will be hosting a conference call, as well as a live webcast on the Investor Relations section of its corporate website at www.alimerasciences.com, on August 10, 2015 at 4:30 P.M. ET to discuss its second quarter ended June 30, 2015 financial results and to provide regulatory and commercial updates. The full text of the press release, which includes information regarding Alimera’s use of non-GAAP financial measures, is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Various statements to be made during the conference call and webcast are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the ability of physicians to obtain reimbursement for ILUVIEN, the acceptance by U.S. physicians of patient results in Europe, the rate of adoption of ILUVIEN in the U.S., Alimera’s ability to increase sales in the U.S. market, and future sales of ILUVIEN in the U.K. and Germany. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “contemplate,” “predict,” “project,” “target,” “likely,” “potential,” “continue,” “ongoing,” “will,” “would,” “should,” “could,” or the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, uncertainty as to Alimera's ability to commercialize, and market acceptance of, ILUVIEN in the U.S. and the European Union, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2014 and Alimera’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, which are on file with the Securities and Exchange Commission (“SEC”) and available free of charge on the SEC’s website at www.sec.gov. Additional factors may also be set forth in those sections of Alimera’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, to be filed with the SEC in the third quarter of 2015. In addition to the risks described above and in Alimera’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All forward-looking statements made during the conference call are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date on which they are made (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
The information in Item 2.02 of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |
99.1 | Press Release of Alimera Sciences, Inc. dated August 10, 2015 | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALIMERA SCIENCES, INC. | ||
Dated: August 10, 2015 | By: | /s/ RICHARD S. EISWIRTH, JR. |
Name: | Richard S. Eiswirth, Jr. | |
Title: | Chief Operating Officer and Chief Financial Officer | |
EXHIBIT INDEX
Exhibit No. | Description | |
99.1 | Press Release of Alimera Sciences, Inc. dated August 10, 2015 | |
Exhibit 99.1
Alimera Sciences Reports Second Quarter 2015 Financial Results
Year Over Year Revenue Growth of 164%
Downstream Demand From Q1 2015 Increases 180%
Company to Host Conference Call Today at 4:30 p.m. EDT
ATLANTA, August 10, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the second quarter ended June 30, 2015.
“The second quarter was our first full quarter of ILUVIEN® sales in the U.S., and we are very pleased with the results. In particular, ILUVIEN generated $3.8 million in sales in the U.S., which accounted for approximately 66% of our total revenue for the quarter with downstream demand from physicians increasing 180% from the first quarter of 2015,” Dan Myers, Alimera president and chief executive officer said. “While it is encouraging to see such initial strength in uptake, we believe we are just scratching the surface of this market opportunity. We expect to see continuing increases as U.S. physicians experience similar patient outcomes as we have seen in Europe and as they begin receiving more insurance payments.”
Mr. Myers continued, “As we continue to grow sales in the U.S. market, we also remain focused on the global ILUVIEN market. We continue to see strength in the United Kingdom and our ongoing efforts to relaunch in Germany have also begun to show a positive impact.”
Second Quarter 2015 Financial Results
Total net revenue increased by approximately $3.6 million, or 164%, to $5.8 million for the second quarter of 2015, compared to net revenue of $2.2 million in the second quarter of 2014. This increase was primarily driven by sales of ILUVIEN in the U.S. where it was launched in the first quarter of 2015.
Revenue in the U.S. grew 58% sequentially from $2.4 million in the first quarter of 2015 to $3.8 million in the current quarter. However, first quarter revenue included initial stocking sales to Alimera’s specialty distributors. Downstream sales from those specialty distributors to physicians and pharmacies increased 180% from quarter to quarter.
International revenue grew 33% sequentially from $1.5 million in the first quarter of 2015 to $2.0 million in the second quarter as a result of increased sales in the United Kingdom, Germany and Portugal.
Cost of goods sold, excluding depreciation and amortization was approximately $380,000 for the three months ended June 30, 2015 and for the three months ended June 30, 2014. Increases in cost of goods sold of $190,000 were a result of sales in the U.S., and were offset primarily by a decrease of $210,000 attributable to a reserve for German inventory recorded in the second quarter of 2014.
Research, development and medical affairs expenses for the second quarter of 2015 increased by approximately $1.9 million, or 100%, to $3.8 million, compared to $1.9 million in the second quarter of 2014, primarily as a result of increased spending on clinical trials, medical science liaisons and scientific communications to further the understanding of ILUVIEN in the medical community.
General and administrative expenses for the second quarter of 2015 increased by approximately $1.0 million, or 36%, to $3.8 million, compared to $2.8 in the second quarter of 2014. This increase was primarily attributable to increased employee costs associated with our growth to support the launch of ILUVIEN in the U.S. and our international growth.
Sales and marketing expenses for the second quarter of 2015 increased by approximately $3.9 million, or 130%, to $6.9 million, compared to $3.0 million in the second quarter of 2014. This increase was primarily attributable to increased personnel and travel costs associated with the hiring of a U.S. field force following the FDA approval of ILUVIEN, as well as increased promotional and marketing costs associated with the launch and commercialization of ILUVIEN in the U.S.
GAAP net loss applicable to common stockholders for the second quarter of 2015 was $8.6 million, compared with GAAP net income applicable to common stockholders of $1.1 million for the second quarter of 2014. GAAP net loss attributable to common stockholders for the quarters ended June 30, 2015 and 2014 was affected by certain non-cash items, including changes in the fair value of a derivative warrant liability, unrealized foreign currency gains and losses, and reserves for potential inventory expiration. GAAP basic and diluted net loss per share for the second quarter of 2015 was $(0.19) per share, based on 44,396,656 weighted average shares outstanding, compared with GAAP basic earnings per share and diluted loss per share for the second quarter of 2014 of $0.03 per share and $(0.16) per share, respectively, based on 40,275,638 and 42,548,254 weighted average shares outstanding, respectively.
Non-GAAP adjusted net loss attributable to common stockholders for the second quarter of 2015 was $10.9 million, compared to a non-GAAP adjusted net loss attributable to common stockholders for the second quarter of 2014 of $6.1 million. Non-GAAP adjusted basic loss per share for the second quarter of 2015 and 2014 were $(0.25) per share and $(0.15) per share, respectively. Non-GAAP adjusted diluted loss per share is not presented as all outstanding common stock equivalents are anti-dilutive. Net loss for basic weighted average shares outstanding attributable to common stockholders per share and non-GAAP adjusted net loss attributable to common stockholders per share was based on 44,396,656 weighted average shares outstanding for the second quarter of 2015 and 40,275,638 weighted average shares outstanding for the second quarter of 2014.
Reconciliations of GAAP cost of goods sold to non-GAAP adjusted costs of goods sold, GAAP gross profit to non-GAAP adjusted gross profit, GAAP net loss attributable to common stockholders to non-GAAP adjusted net loss attributable to common stockholders and GAAP net loss per share to non-GAAP adjusted net loss per share is included below under the heading "Non-GAAP Financial Measures."
As of June 30, 2015, Alimera had cash and cash equivalents of approximately $48.1 million, compared to approximately $61.3 million as of March 31, 2015.
Conference Call to be Held Today
Alimera will hold a conference call today at 4:30 p.m. EDT to discuss these results and provide commercial and other business updates. Dan Myers, President and Chief Executive Officer, and Rick Eiswirth, Chief Operating Officer and Chief Financial Officer, will host the conference call.
To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or (253) 237-1165 (International). A live webcast will be available on the Investor Relations section of the corporate website at http://www.alimerasciences.com.
A replay of the conference call will be available beginning on August 10, 2015 at 6:30 p.m. ET and ending on August 16, 2015 at 11:59 p.m. ET. The replay can be accessed by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 98389468. A replay of the webcast will also be available on the corporate website.
About ILUVIEN
ILUVIEN® is approved for marketing in Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, the United Kingdom, and the U.S., and is commercially available in the U.S., the United Kingdom, Germany and Portugal.
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In Europe, ILUVIEN is approved for vision impairment associated with chronic DME considered insufficiently responsive to available therapies. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months.
Corticosteroids have a history of effective use in treating ocular disease inflammation. ILUVIEN is injected in the back of the patient's eye with an applicator that employs a 25-gauge needle, which allows for a self-sealing wound. In the FAME™ Study, a phase 3 clinical study of ILUVIEN, the primary endpoint of improvement in vision of 15 letters or more was demonstrated at 24 months and the most frequently reported adverse drug reactions included cataract development and increased ocular pressure.
ILUVIEN Important Safety Information
Contraindications
• | ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases. |
• | ILUVIEN is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8. |
• | ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product. |
Warnings and Precautions
• | Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection. |
• | Use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection. |
• | Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber. |
Adverse Reactions
• | In controlled studies, the most common adverse reactions reported were cataract development (ILUVIEN 82%; sham 50%) and intraocular pressure elevation of greater than 10 mmHg (ILUVIEN 34%; sham 10%). |
Patients are advised to have follow-up eye examinations at appropriate intervals following treatment with ILUVIEN. For full prescribing information, log onto www.ILUVIEN.com.
To report suspected adverse reactions, contact Alimera Sciences, Inc. at 1-844-445-8843 or FDA at 1‑800-FDA-1088 or www.fda.gov/medwatch.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera’s European operations are conducted from London by its subsidiary, Alimera Sciences Limited, which has offices in Aldershot, United Kingdom, Berlin, Germany and Lisbon, Portugal.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera’s European operations are conducted from London by its subsidiary, Alimera Sciences Limited, which has offices in Aldershot, United Kingdom, Berlin, Germany and Lisbon, Portugal.
Non-GAAP Financial Measures
Alimera believes the metrics non-GAAP adjusted cost of goods sold, non-GAAP adjusted gross profit, non-GAAP adjusted net loss attributable to common stockholders and non-GAAP adjusted net loss per share are useful financial measures for investors in evaluating Alimera's performance for the periods presented. Non-GAAP adjusted net loss attributable to common stockholders and non-GAAP adjusted net loss per share exclude certain non-cash items. These non-GAAP metrics, however, are not measures of financial performance under accounting principles generally accepted in the United States (GAAP) and should not be considered a substitute for net loss attributable to common stockholders or net loss per share in accordance with GAAP and may not be comparable to similarly titled measures reported by other companies. Alimera's management believes that these non-GAAP metrics are useful supplements for it and investors to Alimera's GAAP financial information because these measures exclude non-cash items which management believes are not reflective of Alimera's operating results. These non-GAAP financial measures also facilitate management's internal comparison to Alimera's historical financial performance and the financial performance of other companies. However, non-GAAP financial measures should only be read in conjunction with financial information reported under GAAP when understanding Alimera's operating performance. For a reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measure, see the table below.
Forward Looking Statements
This press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the ability of physicians to obtain reimbursement
for ILUVIEN, the acceptance by U.S. physicians of patient results in Europe, the rate of adoption of ILUVIEN in the U.S., Alimera’s ability to increase sales in the U.S. market, and future sales of ILUVIEN in the U.K. and Germany. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, uncertainty as to Alimera's ability to commercialize, and market acceptance of, ILUVIEN in the U.S. and Europe, including physician’s ability to obtain reimbursement, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2014 and Alimera’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at http://www.sec.gov. Additional factors may also be set forth in those sections of Alimera’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, to be filed with the SEC in the third quarter of 2015.
In addition to the risks described above and in Alimera's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera's results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
The Ruth Group
David Burke
646-536-7009
ALIMERA SCIENCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2015 AND 2014
(in thousands, except share and per share data)
Three Months Ended, June 30, | Six Months Ended, June 30, | ||||||||||||||
2015 | 2014 | 2015 | 2014 | ||||||||||||
(unaudited) | |||||||||||||||
NET REVENUE | $ | 5,776 | $ | 2,190 | $ | 9,714 | $ | 4,274 | |||||||
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION | (376 | ) | (376 | ) | (659 | ) | (940 | ) | |||||||
GROSS PROFIT | 5,400 | 1,814 | 9,055 | 3,334 | |||||||||||
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES | 3,815 | 1,942 | 7,144 | 4,696 | |||||||||||
GENERAL AND ADMINISTRATIVE EXPENSES | 3,821 | 2,791 | 7,440 | 5,685 | |||||||||||
SALES AND MARKETING EXPENSES | 6,925 | 3,003 | 14,054 | 6,286 | |||||||||||
DEPRECIATION AND AMORTIZATION | 639 | 36 | 1211 | 69 | |||||||||||
OPERATING EXPENSES | 15,200 | 7,772 | 29,849 | 16,736 | |||||||||||
NET LOSS FROM OPERATIONS | (9,800 | ) | (5,958 | ) | (20,794 | ) | (13,402 | ) | |||||||
INTEREST EXPENSE, NET AND OTHER | (1,151 | ) | (325 | ) | (2,273 | ) | (454 | ) | |||||||
UNREALIZED FOREIGN CURRENCY GAIN (LOSS), NET | 143 | (146 | ) | 29 | (202 | ) | |||||||||
CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY | 2,216 | 8,054 | 4,722 | (5,076 | ) | ||||||||||
LOSS ON EARLY EXTINGUISHMENT OF DEBT | — | (440 | ) | — | (440 | ) | |||||||||
NET (LOSS) INCOME BEFORE TAXES | (8,592 | ) | 1,185 | (18,316 | ) | (19,574 | ) | ||||||||
PROVISION FOR TAXES | (4 | ) | (69 | ) | (73 | ) | (69 | ) | |||||||
NET (LOSS) INCOME APPLICABLE TO COMMON STOCKHOLDERS | $ | (8,596 | ) | $ | 1,116 | $ | (18,389 | ) | $ | (19,643 | ) | ||||
NET (LOSS) INCOME PER SHARE APPLICABLE TO COMMON STOCKHOLDERS - Basic | $ | (0.19) | $ | 0.03 | $ | (0.41) | $ | (0.52) | |||||||
WEIGHTED AVERAGE SHARES OUTSTANDING - Basic | 44,396,656 | 40,275,638 | 44,372,283 | 38,076,968 | |||||||||||
NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS - Diluted | $ | (0.19) | $ | (0.16) | $ | (0.41) | $ | (0.52) | |||||||
WEIGHTED AVERAGE SHARES OUTSTANDING - Diluted | 44,396,656 | 42,548,254 | 44,372,283 | 38,076,968 | |||||||||||
ALIMERA SCIENCES, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
June 30, 2015 | December 31, 2014 | |||||
(unaudited) | ||||||
CURRENT ASSETS: | ||||||
Cash and cash equivalents | $ | 48,136 | $ | 76,697 | ||
Accounts receivable, net | 7,732 | 850 | ||||
Prepaid expenses and other current assets | 3,104 | 3,234 | ||||
Inventory, net | 1,638 | 1,734 | ||||
Deferred financing costs | 532 | 754 | ||||
Total current assets | 61,142 | 83,269 | ||||
PROPERTY AND EQUIPMENT, net | 2,659 | 1,653 | ||||
INTANGIBLE ASSET, net | 23,528 | 24,490 | ||||
TOTAL ASSETS | $ | 87,329 | $ | 109,412 | ||
CURRENT LIABILITIES: | ||||||
Accounts payable | $ | 3,284 | $ | 5,021 | ||
Accrued expenses | 2,850 | 954 | ||||
Accrued milestone payments | — | 2,000 | ||||
Outsourced services payable | 961 | 1,466 | ||||
Note payable | 7,672 | 1,023 | ||||
Capital lease obligations | 204 | 11 | ||||
Total current liabilities | 14,971 | 10,475 | ||||
NON-CURRENT LIABILITIES: | ||||||
Derivative warrant liability | 11,376 | 16,098 | ||||
Note payable, net of discount — less current portion | 26,688 | 33,065 | ||||
Other non-current liabilities | 963 | 255 | ||||
COMMITMENTS AND CONTINGENCIES | ||||||
STOCKHOLDERS’ EQUITY: | ||||||
Preferred stock | ||||||
Series A Convertible Preferred Stock | 19,227 | 19,227 | ||||
Series B Convertible Preferred Stock | 49,568 | 49,568 | ||||
Common stock | 444 | 443 | ||||
Additional paid-in capital | 295,339 | 292,851 | ||||
Common stock warrants | 1,497 | 1,497 | ||||
Accumulated deficit | (331,644) | (313,255) | ||||
Accumulated other comprehensive loss | (1,100) | (812) | ||||
TOTAL STOCKHOLDERS’ EQUITY | 33,331 | 49,519 | ||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 87,329 | $ | 109,412 | ||
RECONCILIATION OF GAAP MEASURES TO NON-GAAP ADJUSTED MEASURES
(in thousands, except share and per share data)
Three Months Ended, June 30, | Six Months Ended, June 30, | ||||||||||||||
2015 | 2014 | 2015 | 2014 | ||||||||||||
(Unaudited) | |||||||||||||||
GAAP COST OF GOODS SOLD | $ | (376) | $ | (376) | $ | (659) | $ | (940) | |||||||
Adjustments to costs of goods sold: | |||||||||||||||
Reserve for potential product expiration | 56 | 207 | 59 | 654 | |||||||||||
NON-GAAP ADJUSTED COST OF GOODS SOLD | $ | (320) | $ | (169) | $ | (600) | $ | (286) | |||||||
GAAP GROSS PROFIT | $ | 5,400 | $ | 1,814 | $ | 9,055 | $ | 3,334 | |||||||
Adjustments to gross profit: | |||||||||||||||
Reserve for potential product expiration | 56 | 207 | 59 | 654 | |||||||||||
NON-GAAP ADJUSTED GROSS PROFIT | $ | 5,456 | $ | 1,955 | $ | 9,114 | $ | 3,988 | |||||||
GAAP NET (LOSS) INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS | $ | (8,596) | $ | 1,116 | $ | (18,389) | $ | (19,643) | |||||||
Adjustments to net (loss) income: | |||||||||||||||
Unrealized foreign currency (gain) loss, net | (143) | 146 | (29) | 202 | |||||||||||
Loss on early extinguishment of debt | — | 440 | — | 440 | |||||||||||
Change in fair value of derivative warrant liability | (2,216) | (8,054) | (4,722) | 5,076 | |||||||||||
Reserve for potential product expiration | 56 | 207 | 59 | 654 | |||||||||||
NON-GAAP ADJUSTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | $ | (12,182) | $ | (6,145) | $ | (23,081) | $ | (13,271) | |||||||
GAAP NET (LOSS) INCOME PER SHARE - Basic | $ | (0.19) | $ | 0.03 | $ | (0.41) | $ | (0.52) | |||||||
Adjustments to net (loss) Income: | |||||||||||||||
Unrealized foreign currency (gain) loss, net | (0.00) | 0.00 | (0.00) | 0.01 | |||||||||||
Loss on early extinguishment of debt | — | 0.01 | — | 0.01 | |||||||||||
Change in fair value of derivative warrant liability | (0.05) | (0.20) | (0.11) | 0.13 | |||||||||||
Reserve for potential product expiration | 0.00 | 0.01 | 0.00 | 0.02 | |||||||||||
NON-GAAP ADJUSTED NET LOSS PER SHARE - Basic | $ | (0.25) | $ | (0.15) | $ | (0.52) | $ | (0.35) | |||||||
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic | 44,396,656 | 40,275,638 | 44,372,283 | 38,076,968 | |||||||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Craig-Hallum Assumes Alimera Sciences (ALIM) at Buy
- Earthquakes Announce Udemy as Official Learning and Skills Partner and Official Training Jersey Partner
- Maryland CareerQuest Connects Area Students with Training and Education Opportunities for Hands-On Careers
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
